The FDA Center for Drug Evaluation and Research has accepted a letter of intent for the first biomarker for idiopathic pulmonary fibrosis into its Biomarker Qualification Program, according to a press ...
Discusses 2026 Clinical Pipeline Outlook and Anticipated Trial Updates February 2, 2026 7:01 PM ESTCompany ParticipantsGary ...
BPC-157 hasn't been approved by the FDA. But that hasn't stopped this buzzy drug from gaining traction – and attention from MAHA.
AI is rapidly transforming hospital medicine by supporting clinical workflows, enhancing decision-making, and reducing ...
The gray market is awash with BPC-157, a drug hyped as a cure-all, but unapproved by the FDA. Will RFK Jr. change that?
Premenopausal women presenting with acute coronary syndrome (ACS) are a unique and often underrecognized patient population. Although they are traditionally considered at lower cardiovascular risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results